Abstract
The extent to which genetic variation at the APOE locus explains the burden of late-onset Alzheimer’s disease (AD) is poorly understood. We provide new estimates of the proportions of AD and all-cause dementia attributable to carriage of ε3 and/or ε4 alleles of APOE, using data from 171,133 participants of the UK Biobank cohort study. AD and all-cause dementia were ascertained at baseline and during follow-up via linked electronic health records for up to 16.8 years. We estimate that 74.5% (95% CI: 38.6, 89.4) of AD and 39.5% (95% CI: 10.7, 59.1%) of all-cause dementia burden is attributable to ε3 and ε4 carriage. Thus, differences in the molecular physiology of apolipoprotein E cause most AD and a large fraction of all dementia. Research into this pathway should be prioritised to facilitate dementia prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The MRC Unit for Lifelong Health and Ageing at UCL is funded by the Medical Research Council (MC_UU_00019/3). NMD is supported via a Norwegian Research Council Grant number 295989. ELA is supported by a UKRI Future Leaders Fellowship (MR/W011581/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
North West Haydock Research Ethics Committee of the UK Health Research Authority gave ethical approval for the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We added new analysis of the burden of AD attributable to APOE e3 and e4 alleles separately, and included a comparison of the burden of AD attributable to e3 and e4 with other genetic risk loci for AD and attributable fractions for the top ten genetic risk loci for coronary heart disease (figure 1). We also implemented minor analytical changes to the main modelling.
Data Availability
All data used in this research are available to researchers that register with UK Biobank and request access to them as part of an approved project.
